KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Deferred Taxes (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Deferred Taxes for 14 consecutive years, with $96.0 million as the latest value for Q1 2026.

  • For Q1 2026, Deferred Taxes fell 30.98% year-over-year to $96.0 million; the TTM value through Mar 2026 reached $742.3 million, up 5.14%, while the annual FY2025 figure was $785.4 million, 3.71% up from the prior year.
  • Deferred Taxes hit $96.0 million in Q1 2026 for Regeneron Pharmaceuticals, down from $232.5 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $286.3 million in Q4 2023 and bottomed at $85.7 million in Q3 2022.
  • Average Deferred Taxes over 5 years is $189.6 million, with a median of $190.4 million recorded in 2024.
  • Year-over-year, Deferred Taxes soared 2327.72% in 2022 and then plummeted 43.57% in 2024.
  • Regeneron Pharmaceuticals' Deferred Taxes stood at $279.7 million in 2022, then grew by 2.36% to $286.3 million in 2023, then decreased by 2.13% to $280.2 million in 2024, then fell by 17.02% to $232.5 million in 2025, then plummeted by 58.71% to $96.0 million in 2026.
  • According to Business Quant data, Deferred Taxes over the past three periods came in at $96.0 million, $232.5 million, and $278.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.